reports
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results a...
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update Commercial launch of INPEFA® (sotagliflozin) for Heart Failure continues to progress Resubmission of NDA for ZYNQUISTA™ (sotagliflozin) in Type 1 Diabetes expected mid-year 2024 Start-up ongoing for Phase 3 study of sotagliflozin in Hypertrophic Cardiomyopathy, with enrollment expected to begin mid-year 2024 Enrollment in Phase 2b PROGRESS study of LX9211 in Diabetic Peripheral Neuropathic Pain on track for expected Q2 2025 topline data Conference Call and Webcast at 5:00 pm Eastern Time ...
Lonnel Coats Retires as Chief Executive Officer and Board Member of Le...
Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that Lonnel Coats has provided notice of his retirement as chief executive officer and as a member of its board of directors, in each case effective July 7, 2024, his 10th anniversary with the company. The board of directors has initiated a search for a new chief executive officer which will consider both internal and external candidates. “During Mr. Coats’ tenure, Lexicon advanced two compounds through clin...
Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results C...
Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024 THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) will release its first quarter 2024 financial results on Thursday, May 2, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update. Dial-in InformationU.S. Dial-in Number: (888) 317-6003International Dial-in Number: (412) 317-6061Conference ID: 5993982 Replay Informatio...
Lexicon Pharmaceuticals to Host 2024 Investor Day
Lexicon Pharmaceuticals to Host 2024 Investor Day Includes Business and Scientific Updates from Lexicon Executives and Leading Medical Experts in Hypertrophic Cardiomyopathy, Type 1 Diabetes and Diabetic Peripheral Neuropathic Pain THE WOODLANDS, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that senior company executives will be joined by leading physicians at the Lexicon 2024 Investor Day on April 22, 2024. The event will be held in New York City from 9:00 a.m. to 12:00 p.m. ET. Business and scientific updates will be presented by Lonnel Coats, Lexicon’s c...
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virt...
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference THE WOODLANDS, Texas, April 03, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer, will participate in a moderated discussion at the 23rd Annual Needham Virtual Healthcare conference Wednesday April 10th, 1:30-2:10pm. A simultaneous webcast will be available in the...
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attac...
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two sodium glucose transport proteins (SGLT2 and SGLT1), will be delivered during the American College of Cardiology 73rd Annual Scientific Session & Expo being held April 6 - 8, 2024 in Atlanta, Georgia, including results from a post-hoc ...
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In ...
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that a post hoc analysis of clinical data from its inTandem3 Phase 3 trial demonstrated that treatment with sotagliflozin resulted in improved glycemic control in patients with type 1 diabetes and chronic kidney disease (CKD). In this important patient population, treatment with sotagliflozin successfully lowered A1C, body weigh...
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results ...
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update Commercial launch of INPEFA® (sotagliflozin) continues to progress. with increasing demand across the cardiology community and improving payer access Patient enrollment underway in PROGRESS, a Phase 2b study of LX9211 in Diabetic Peripheral Neuropathic Pain; topline data anticipated Q2 2025 Preparations underway for Phase 3 study of sotagliflozin in Hypertrophic Cardiomyopathy and resubmission of NDA for sotagliflozin in Type 1 Diabetes Recent Successful Capital Raise Supports Company Initi...
Lexicon Announces Oversubscribed $250 Million Private Placement of Equ...
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced it has entered into a securities purchase agreement (the “purchase agreement”) for a private investment in public equity financing that is expected to result in gross proceeds of approximately $250 million, before deducting placement agent fees and offering expenses. Pursuant to the terms of the purchase agreement, Lexicon will sell approximately 2.3 million shares of series a ...
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Fo...
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA Preparations Underway for Resubmission of New Drug Application for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in Patients with Type 1 Diabetes and Chronic Kidney Disease Resubmission is Anticipated Mid-2024 THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX), today announced that, following the receipt of recent feedback from FDA, it is preparing to resubmit its New Drug Application (NDA) for sotagliflozin as an adjunct to insulin therapy for gly...
Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd ...
Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference -INPEFA® Launch Positioned for Acceleration in 2024- -Clinical Data and FDA Feedback Support INPEFA Life Cycle Management Opportunity in Hypertrophic Cardiomyopathy- -LX9211 Late-Stage Development Underway, with Potential to Be First New Non-Opioid Drug for Diabetic Peripheral Neuropathic Pain in Over Two Decades- -Company Presentation January 11, 2024 at 10:30am PST (1:30pm ET)- THE WOODLANDS, Texas, Jan. 08, 2024 (GL...
Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Hea...
Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference THE WOODLANDS, Texas, Dec. 21, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced its participation in the 42nd Annual JPMorgan Healthcare Conference taking place January 8 – January 12, 2024. Lonnel Coats, Lexicon’s chief executive officer, will make a company presentation at 10:30am PT / 1:30 pm ET on Thursday, January 11th. Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, and Craig Granowitz, M.D., Ph.D., Le...
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in ...
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain in more than 20 years LX9211 has previously received Fast Track designation from the U.S. Food and Drug Administration (FDA) for DPNP THE WOODLANDS, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that it has enrolled the first patient in PROGRESS (A Ph...
Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandle...
Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference THE WOODLANDS, Texas, Nov. 22, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2023: 35th Annual Piper Sandler Healthcare Conference6th Annual Evercore ISI HealthCONx Conference Lonnel Coats, Lexicon’s chief executive officer, Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief ...
Lexicon Pharmaceuticals Inc: 1 director
A director at Lexicon Pharmaceuticals Inc bought 200,000 shares at 1.008USD and the significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in ...
INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk reductions in heart failure and separately in MACE related outcomes as early as approximately three months in patients at high risk for cardiovascular events INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Nov. 12, 2023 (GLOBE NEWSWIRE...
Lexicon Pharmaceuticals to Participate in the Jefferies London Healthc...
Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference THE WOODLANDS, Texas, Nov. 10, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced its participation in the Jefferies London Healthcare Conference taking place November 14-16, 2023. Jeff Wade, Lexicon’s president and chief financial officer, and Tom Garner, Lexicon’s senior vice president and chief commercial officer, will make a company presentation at 5:00 pm GMT / 12:00 pm EST on Wednesday, November 15th. A simultaneous webcast of the presentation will be available in the “Events” section of the...
Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results a...
Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update Commercial launch of INPEFA® (sotagliflozin) as a differentiated, new treatment option for heart failure patients shows meaningful progress in Q3 with increasing demand across the cardiology community Significant formulary inclusions effective in Q4 opening the opportunity for further commercial acceleration into 2024 and beyond LX9211 moving into late-stage development for the treatment of diabetic peripheral neuropathic pain Conference Call and Webcast at 8:00 am Eastern Time THE ...
Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results C...
Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023 THE WOODLANDS, Texas, Nov. 03, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) will release its third quarter 2023 financial results on Wednesday, November 8th, 2023 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a.m. CT) that day to discuss the financial results and to provide a business update. Dial-in InformationU.S. Dial-in Number: (888) 317-6003International Dial-in Number: (412) 317-6061Conference ID: 2598226 Repla...
Data on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Amo...
Data on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023 Cost-effectiveness data and analyses of financial impact among patients hospitalized for heart failure and treated with INPEFA included as important data selected for presentation INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that five data presentations related to INPEFA® (sotagliflozin) will be del...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.